ZIMBUS BREEZHALER 114/46/68 indacaterol/glycopyrronium/mometasone furoate 114/46/68 microgram powder for inhalation in capsule with inhaler

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

glycopyrronium bromide, Quantity: 63 microgram (Equivalent: glycopyrronium, Qty 50 microgram); mometasone furoate, Quantity: 80 microgram; indacaterol acetate, Quantity: 173 microgram (Equivalent: indacaterol, Qty 150 microgram)

Mevcut itibaren:

Grand Medical Pty Ltd

Farmasötik formu:

Capsule, hard

Kompozisyon:

Excipient Ingredients: lactose monohydrate; magnesium stearate

Uygulama yolu:

Inhalation

Paketteki üniteler:

10 capsules + 1 inhaler (sample and commercial packs), 30 capsules + 1 inhaler

Reçete türü:

(S4) Prescription Only Medicine

Terapötik endikasyonlar:

Zimbus Breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Ürün özeti:

Visual Identification: White to practically white powder in a hard hypromellose capsule of size 3 with green transparent cap and uncoloured transparent body with a white marking on the cap and 'IGM150-50-80' printed in black on the body; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

Yetkilendirme durumu:

Registered

Yetkilendirme tarihi:

2022-07-07